Uptake and biodistribution of rizatriptan to blood and brain following different routes of administration in rats

International Journal of Pharmaceutics

Volumn 337, Issue 1-2, 2007, Pages 155-160

  Wang, Chun ^a   Quan, Li Hui ^a   Guo, Yi ^a   Liu, Chun Yu ^a   Liao, Yong Hong ^a  

^a INSTITUTE OF MEDICINAL PLANT DEVELOPMENT   (China)

Author keywords

Intranasal delivery; Intratracheal instillation; Nose brain drug transport; Pulmonary delivery; Rizatriptan; Subcutaneous delivery

Indexed keywords

RIZATRIPTAN;

ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG INSTILLATION; DRUG UPTAKE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; WISTAR RAT;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BLOOD-BRAIN BARRIER; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; INJECTIONS, SUBCUTANEOUS; INTUBATION, INTRATRACHEAL; MALE; METABOLIC CLEARANCE RATE; RATS; RATS, WISTAR; SEROTONIN AGONISTS; TRIAZOLES; TRYPTAMINES;

EID: 34248654863     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2006.12.039     Document Type: Article

References (23)

1. Ahn H., and Basbaum A.I. Where do triptans act in the treatment of migraine?. Pain 115 (2005) 1-4
2. Anand Kumar T.C., David G.F.X., Umberkoman B., and Saini K.D. Uptake of radioactivity by body fluids and tissues in rhesus monkeys after intravenous injection or intranasal spray of tritium-labelled oestradiol and progesterone. Curr. Sci. 43 (1974) 435-439
3. Cady P.K., Wendt J.K., Kirchner J.R., Sargent J.D., Rothrock J.F., and Skaggs Jr. H. Treatment of acute migraine with subcutaneous sumatriptan. JAMA 265 (1991) 2831-2835
4. Chen J., Jiang X.G., Jiang W.M., Mei N., Gao X.L., and Zhang Q.Z. Liquid chromatographic method for the determination of rizatriptan in human plasma. J. Chromatogr. B 805 (2004) 169-173
5. Cumberbatch M.J., Hill R.G., and Hargreaves R.J. Rizatriptan has central antinociceptive effects against durally evoked responses. Eur. J. Pharmacol. 328 (1997) 37-40
6. Duquesnoy C., Mamet J.P., Sumner D., and Fuseau E. Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration. Eur. J. Pharm. Sci. 6 (1998) 99-104
7. Gladstone J.P., and Gawel M. Newer formulations of the triptans: advances in migraine management. Drugs 63 (2003) 2285-2305
8. Goadsby P.J., and Hoskin K.L. Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)1B/receptor agonist zolmitriptan (311C90): are brain stem sites therapeutic target in migraine?. Pain 67 (1996) 355-359
9. Goadsby P.J., and Knight Y. Inhibition of trigeminal neurones after intravenous administration of naratriptan through an action at 5-hydroxytryptamine (5-HT1B/1D) receptors. Br. J. Pharmacol. 122 (1997) 918-922
10. Illum L. Nasal drug delivery: new developments and strategies. Drug Discov. Today 7 (2002) 184-1189
11. Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur. J. Pharm. Sci. 11 (2000) 1-18
12. Lacey L.F., Keene O.N., Duquesnoy C., and Bye A. Evaluation of different indirect measures of rate of drug absorption in comparative pharmacokinetic studies. J. Pharm. Sci. 83 (1994) 212-215
13. Lizio R., Westhof A., Lehr C.M., and Klenner T. Oral endotracheal intubation of rats for intratracheal instillation and aerosol drug delivery. Lab. Animal 35 (2001) 257-260
14. Lipton R.B., Hamelsky S.W., and Dayno J.M. What do patients with migraine want from acute migraine treatment?. Headache 42 (2002) 3-9
15. Mathew N.T., and Loder E.W. Evaluating the triptans. Am. J. Med. 118 (2005) 28S-35S
16. Milton K.A., Scott N.R., Allen M.J., Abel S., Jenkins V.C., James G.C., Rance D.J., and Eve M.D. Pharmacokinetics, pharmacodynamics, and safety of the 5-HT1B/1D agonist eletriptan following intravenous and oral administration. J. Clin. Pharmacol. 42 (2002) 528-539
17. Rabinowitz J.D., Wensley M., Lloyd P., Myers D., Shen W., Lu A., Hodges C., Hale R., Mufson D., and Zaffaroni A. Fast onset medications through thermally generated aerosols. J. Pharmacol. Exp. Ther. 309 (2004) 769-775
18. 1 antagonist CP-99,994 on plasma extravasation in dura mater and c-fos mRNA expression in trigeminal nucleus caudalis of rats. Neuropharmacology 34 (1995) 255-261
19. Tfelt-Hansen P., De Vries P., and Saxena P.R. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 60 (2000) 1259-1287
20. Van den Berg M.P., Romeijn S.G., Verhoef J.C., and Merkus F.W.H.M. Serial cerebrospinal fluid sampling in a rat model to study drug uptake from the nasal cavity. J. Neurosci. Methods 116 (2002) 99-107
21. Vyas K.P., Halpin R.A., Geer L.A., Ellis J.D., Liu L., Cheng H., Chavez-Eng C., Matuszewski B.K., Varga S.L., Guiblin A.R., and Rogers J.D. Disposition and pharmacokinetics of the antimigraine drug, rizatriptan, in humans. Drug Metab. Dispos. 28 (2000) 89-95
22. Vyas T.K., Babbar A.K., Sharma R.K., Singh S., and Misra A. Preliminary brain-targeting studies on intranasal mucoadhesive microemulsions of sumatriptan. AAPS PharmSciTech. 7 (2006) E1-E9
23. Williamson D.J., Shepheard S.L., Hill R.G., and Hargreaves R.J. The novel anti-migraine agent rizatriptan inhibits neurogenic dural vasodilation and extravasation. Eur. J. Pharmacol. 328 (1997) 61-64